Sangamo Therapeutics, Inc. (SGMO) — Analyst outlook / Analyst consensus target is. Based on 14 analyst ratings, the consensus is bullish — 6 Buy, 7 Hold, 1 Sell.
The consensus price target is $7.25 (low: $2.00, high: $19.00), representing an upside of 2535.4% from the current price $0.28.
Analysts estimate Earnings Per Share (EPS) of $-0.48 and revenue of $0.06B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-0.49 vs est $-0.48 (missed -2.9%). 2025: actual $-0.44 vs est $-0.31 (missed -42.3%). Analyst accuracy: 84%.
SGMO Stock — 12-Month Price Forecast
$7.25
▲ +2,535.41% Upside
Average Price Target
Based on 14 Wall Street analysts offering 12-month price targets for Sangamo Therapeutics, Inc., the average price target is $7.25, with a high forecast of $19.00, and a low forecast of $2.00.
The average price target represents a +2,535.41% change from the last price of $0.28.
Highest Price Target
$19.00
Average Price Target
$7.25
Lowest Price Target
$2.00
SGMO Analyst Ratings
Hold
Based on 14 analysts giving stock ratings to Sangamo Therapeutics, Inc. in the past 3 months
EPS Estimates — SGMO
84%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$0.49
vs Est –$0.48
▼ 2.9% off
2025
Actual –$0.44
vs Est –$0.31
▼ 29.7% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — SGMO
64%
Analyst Accuracy
Fair
2 years compared
Actual vs Estimate
2024
Actual $0.058B
vs Est $0.062B
▼ 7.2% off
2025
Actual $0.040B
vs Est $0.065B
▼ 65.6% off
Revenue Trend
Revenue has declined over the period shown. Analysts forecast significant revenue growth ahead.
